Literature DB >> 6451065

Immunodeficiency in Down's syndrome: low levels of serum thymic factor in trisomic children.

M Duse, M A Brugo, A Martini, C Tassi, C Ferrario, A G Ugazio.   

Abstract

The activity of thymus-dependent serum factor SF was significantly lower in 18 children wit Down's syndrome (DS) than in 14 matched controls. The percentage of circulating T lymphocytes forming E-rosettes was also low in DS. Together with the previous finding of immature of T lymphocytes in peripheral blood, the present data suggest that the basic immune defect of DS is failure in differentiation of peripheral post-thymic precursors to fully immunocompetent T lymphocytes resulting from lack of thymic hormonal factors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6451065

Source DB:  PubMed          Journal:  Thymus        ISSN: 0165-6090


  5 in total

1.  Immunoregulatory CD4+ CD45R+ suppressor/inducer T lymphocyte subsets and impaired cell-mediated immunity in patients with Down's syndrome.

Authors:  S Raziuddin; M E Elawad
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

2.  Cell-mediated cytotoxicity in Down syndrome: impairment of allogeneic mixed lymphocyte reaction, NK and NK-like activities.

Authors:  D Montagna; R Maccario; A G Ugazio; L Nespoli; E Pedroni; P Faggiano; G R Burgio
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

3.  Lymphocyte subpopulations in Down's syndrome: high percentage of circulating HNK-1+, Leu 2a+ cells.

Authors:  R Maccario; A G Ugazio; L Nespoli; C Alberini; D Montagna; F Porta; F Bonetti; G R Burgio
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

4.  Cell-mediated immunodeficiency in Down's syndrome: normal IL-2 production but inverted ratio of T cell subsets.

Authors:  R Karttunen; T Nurmi; J Ilonen; H M Surcel
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

5.  Natural killer cell function in trisomy-21 (Down's syndrome).

Authors:  T Nurmi; K Huttunen; O Lassila; M Henttonen; A Säkkinen; S L Linna; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.